Page 292 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 11
17. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639- 1650.
18. MO. Dutch Association for Medical Oncology. “Result survey screening for DPD deficiency”. Dutch Medical Oncology Journal. 2016;19(6):12-15.
19. KNMP. Royal Dutch Society for the Advancement of Pharmacy. Fluorouracil/Capecitabine DPD gene activity score and guidelines. [Website]. 2015; https://kennisbank.knmp.nl/article/ farmacogenetica/2552-4893-4894.html. Accessed 05 May 2017.
20. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
21. Henricks LM, Kienhuis E, de Man FM, et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low dose capecitabine. JCO Precis Oncol. 2017.
22. Federa. Federation of Dutch Medical Scientific Societies. www.federa.org.
23. NCI. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. https:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, 5 May 2017.
24. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity
- Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34.
25. van Staveren MC, van Kuilenburg ABP, Guchelaar HJ, et al. Evaluation of an oral uracil loading
test to identify DPD-deficient patients using a limited sampling strategy. Br J Clin Pharmacol.
2016;81(3):553-561.
26. Henricks LM, Siemerink EJM, Rosing H, et al. Capecitabine-based treatment of a patient with a
novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer.
2018;142(2):424-430.
27. Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis
of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46(1):9-
17.
28. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV
neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase
deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer. 2002;101(3):253-258.
29. Regan JF, Kamitaki N, Legler T, et al. A rapid molecular approach for chromosomal phasing. PloS
one. 2015;10(3):e0118270.
30. Buermans HP, Vossen RH, Anvar SY, et al. Flexible and Scalable Full-Length CYP2D6 Long Amplicon
PacBio Sequencing. Hum Mutat. 2017;38(3):310-316.
31. van der Straaten T, Swen J, Baak-Pablo R, Guchelaar HJ. Use of plasmid-derived external quality
control samples in pharmacogenetic testing. Pharmacogenomics. 2008;9(9):1261-1266.
32. ExAC. Exome Aggregation Consortium. ExAC Browser (Beta). 2016; http://exac.broadinstitute.
org/ Accessed 13/12/2017.
33. gnomAD. genome Aggregation Database. gnomAD browser (Beta). 2017; http://gnomad.
broadinstitute.org/. Accessed 14th July 2017.
290